Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177730 | 0.89 | SLC6A3 (0.46) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL27421087 | 0.89 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL1318195 | 0.88 | ALDH1A1 (0.52) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL7965361 | 0.87 | SMN1; SMN2 (0.43) | ALDH1A1POLBSMN1; SMN2HTTLMNA | |
| SCHEMBL16961496 | 0.87 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL429791 | 0.86 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2TDP1MAPTPKM | |
| SCHEMBL14612621 | 0.85 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL4098621 | 0.84 | PDGFRB (0.58) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL30221693 | 0.83 | POLB (0.49) | ALDH1A1POLBSMN1; SMN2HTTTDP1 | |
| SCHEMBL10736359 | 0.83 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4722203-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4622678-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-GUCY2C ANTIBODY AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | Heidelberg Pharma Research GmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250195675-A1 | NEW ANTIBODY-DRUG CONJUGATE AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| EP-0925294-B1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| CN-1211736-A | Use of certain amides as probes for detection of antitubulin activity and resistance monitoring | ROHM & HAAS (US) | 1999-03-24 | — | — | CN | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885POLB 2088/4885SMN1; SMN2 2647/4885 |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | ALDH1A1 2138/4885POLB 4369/4885SMN1; SMN2 3568/4885 |
| US-20250195675-A1 | NEW ANTIBODY-DRUG CONJUGATE AS WELL AS METHODS OF PRODUCTION AND USES THEREOF | GUCY1B2, GUCY1A2, ADCY2 | ALDH1A1 773/4885POLB 4776/4885SMN1; SMN2 1900/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | ALDH1A1 701/4885POLB 4057/4885SMN1; SMN2 1524/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | ALDH1A1 362/4885POLB 2916/4885SMN1; SMN2 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.